Sugi Predict

Sugi Predict / Compounds / SCHEMBL30874384

SCHEMBL30874384

SCHEMBL30874384

CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N)CCC(=O)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 4/20 0.60
▸ BACE2 Q9Y5Z0 4/20 0.60
▸ TFPI P10646 1/20 0.58
▸ GLP1R P43220 5/20 0.56
▸ OPRM1 P35372 1/20 0.56
▸ OPRD1 P41143 1/20 0.56
▸ OPRK1 P41145 1/20 0.56
▸ ECE1 P42892 1/20 0.54
▸ MUS81 Q96NY9 1/20 0.54
▸ NR3C1 P04150 1/20 0.54
▸ CALCR P30988 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30874381 1.00 BACE1 (0.60) BACE1BACE2TFPIGLP1ROPRM1
SCHEMBL30874382 1.00 BACE1 (0.60) BACE1BACE2TFPIGLP1ROPRM1
SCHEMBL30874383 0.97 BACE1 (0.63) BACE1BACE2TFPIGLP1ROPRM1
SCHEMBL30874390 0.95 TFPI (0.63) BACE1BACE2TFPIGLP1RECE1
SCHEMBL30906431 0.94 BACE1 (0.63) BACE1BACE2TFPIGLP1ROPRM1
SCHEMBL30120636 0.92 TFPI (0.66) BACE1BACE2TFPIGLP1RNR3C1
SCHEMBL30721553 0.92 TFPI (0.66) BACE1BACE2TFPIGLP1RECE1
SCHEMBL31182821 0.91 BACE1 (0.57) BACE1BACE2TFPIGLP1ROPRM1
SCHEMBL30721600 0.91 TFPI (0.64) BACE1BACE2TFPIGLP1RECE1
SCHEMBL31000924 0.90 TFPI (0.64) TFPIGLP1ROPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150423-A1 GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES Nanjing Finepeptide Biopharmaceutical Co.,Ltd (CN) 2024-05-09 — — US claimed
US-20240150423-A1 GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES Nanjing Finepeptide Biopharmaceutical Co.,Ltd (CN) 2024-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150423-A1 GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES GLP1R, IAPP, GCG BACE1 1841/4885BACE2 1000/4885TFPI 864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.